Clofarabine

Basic Information

Item Value
DrugBank ID DB00631
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 68

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 myeloid leukemia KG + DL
2 precursor lymphoblastic lymphoma/leukemia KG + DL
3 ganglioneuroblastoma (disease) KG + DL
4 neuroblastoma KG + DL
5 vertebral anomalies and variable endocrine and T-cell dysfunction KG + DL
6 retroperitoneal neoplasm KG + DL
7 blast phase chronic myelogenous leukemia, BCR-ABL1 positive KG + DL
8 acute lymphoblastic leukemia KG + DL
9 chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation KG + DL
10 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma KG + DL
11 Hodgkins lymphoma KG + DL
12 bladder transitional cell carcinoma KG + DL
13 lymphoid neoplasm KG + DL
14 follicular lymphoma KG + DL
15 rheumatoid arthritis KG + DL
16 obsolete Hodgkin’s granuloma KG + DL
17 unclassified myelodysplastic syndrome KG + DL
18 methylcobalamin deficiency type cblE KG + DL
19 fetal akinesia-cerebral and retinal hemorrhage syndrome KG + DL
20 chronic lymphocytic leukemia/small lymphocytic lymphoma KG + DL
21 aregenerative anemia KG + DL
22 refractory cytopenia of childhood KG + DL
23 partial deletion of the long arm of chromosome 5 KG + DL
24 brachydactyly-syndactyly syndrome KG + DL
25 severe congenital hypochromic anemia with ringed sideroblasts KG + DL
26 small cell lung carcinoma KG + DL
27 myelodysplastic syndrome KG + DL
28 chronic myelogenous leukemia, BCR-ABL1 positive KG + DL
29 pulmonary blastoma KG + DL
30 primary pulmonary lymphoma KG + DL
31 ALK-positive large B-cell lymphoma KG + DL
32 colobomatous microphthalmia-rhizomelic dysplasia syndrome KG + DL
33 well-differentiated fetal adenocarcinoma of the lung KG + DL
34 coloboma of optic nerve (disease) KG + DL
35 leukemia (disease) KG + DL
36 neoplasm of immature B and T cells KG + DL
37 lymphoblastic leukemia, acute, with lymphomatous features KG + DL
38 T-cell leukemia KG + DL
39 specific granule deficiency KG + DL
40 classic Hodgkin lymphoma KG + DL
41 acute myeloid leukemia with t(8;21)(q22;q22) translocation KG + DL
42 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) KG + DL
43 neonatal jaundice KG + DL
44 acute myeloid leukemia with CEBPA somatic mutations KG + DL
45 nodular lymphocyte predominant Hodgkin lymphoma KG + DL
46 Hodgkin’s paragranuloma KG + DL
47 Hodgkin’s lymphoma, lymphocytic depletion KG + DL
48 thymic epithelial neoplasm KG + DL
49 acute biphenotypic leukemia KG + DL
50 bulbar polio KG + DL

(Showing top 50 of 68 predictions)

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search


Copyright © 2026 藥提醒科技有限公司 (yao.care). This report is for research purposes only and does not constitute medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.